Rules of tumor cell development and their application to biomarkers for ovarian cancer

Oncology Nursing Forum

Volumn 35, Issue 3, 2008, Pages 403-409

  McLemore, Monica R ^a,b   Miaskowski, Christine ^a,b   Aouizerat, Bradley E ^a,b   Chen, Lee May ^c   Dodd, Marylin ^d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Department of Physiological Nursing ^*

^c Department of Obstetrics Gynecology and Reproductive Sciences   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CADHERIN; DIAGNOSTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH PROMOTOR; INHIBIN; PROTEIN P53; TUMOR MARKER; VASCULOTROPIN A;

APOPTOSIS; BIOLOGICAL MODEL; CELL TRANSFORMATION; COCARCINOGENESIS; FEMALE; HUMAN; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); ONCOLOGY NURSING; OVARY TUMOR; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

APOPTOSIS; CA-125 ANTIGEN; CADHERINS; CELL TRANSFORMATION, NEOPLASTIC; COCARCINOGENESIS; FEMALE; GROWTH SUBSTANCES; HUMANS; INHIBINS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; ONCOLOGIC NURSING; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 45849115870     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/08.ONF.403-409     Document Type: Article

References (46)

1. Alberts. B., Johnson, A., Lewis, J., Raff, M., Roberts, K., & Walter, P. (2002). Molecular biology of the cell (4th ed.). New York: Garland Science.
2. Alvarez-Secord, A., Sayer, R., Snyder, S.A., Broadwater, G., Rodriguez, G.C., Berchuck, A., et al. (2004). The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer. Gynecologic Oncology, 94(1), 74-79.
3. Auersperg, N., Ota, T., & Mitchelle, G.W. (2002). Early events in ovarian epithelial carcinogenesis: Progress and problems in experimental approaches. International Journal of Gynecologic Cancer, 12(6), 691-703.
4. Aunoble, B., Sanches, R., Didier, E., & Bignon, Y.J. (2000). Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer. International Journal of Oncology, 16(3), 567-576.
5. Candido Dos Reis, F.J., Moreira de Andrade, J., & Bighetti, S. (2002). CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors. Gynecologic and Obstetric Investigation, 54(3), 132-136.
6. Chin, D., Boyle, G.M., Parsons, P.G., & Coman, W.B. (2004). What is transforming growth factor-beta (TGF-beta)? British Journal of Plastic Surgery, 57(3), 215-221.
7. Cirisano, F.D., & Karlan, B.Y. (1996). The role of the HER-2/neu oncogene in gynecologic cancers. Journal of the Society for Gynecologic Investigation, 3(3), 99-105.
8. Counter, C.M., Hirte, H.W., Bacchetti, S., & Harley, C.B. (1994). Telomerase activity in human ovarian carcinoma. Proceedings of the National Academy of Sciences. 9/(8), 2900-2904.
9. Evan, G., & Littlewood, T. (1998). A matter of life and cell death. Science, 281(5381), 1317-1322.
10. Faleiro-Rodrigues, C., Macedo-Pinto, I., Pereira, D., Ferreira, V.M., & Lopes, C.S. (2004). Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas. Human Pathology, 35(6), 663-669.
11. Fraser, M., Leung, B., Jahani-Asl, A., Yan, X., Thompson, W.E., & Tsang, B.K. (2003). Chemoresistance in human ovarian cancer: The role of apoptotic regulators. Reproductive Biology and Endocrinology, 1, 66.
12. Fujita, M., Enomoto, T., & Murata, Y. (2003). Genetic alterations in ovarian carcinoma: With specific reference to histological subtypes. Molecular and Cellular Endocrinology, 202(1-2), 97-99.
13. Hahn, W.C., & Weinberg, R.A. (2002). Rules for making human tumor cells. New England Journal of Medicine, 347(20), 1593-1603.
14. Hanahan, D., & Weinberg, R.A. (2000). The hallmarks of cancer. Cell, 100(1), 57-70.
15. Hazelton, D., Nicosia, R.F., & Nicosia, S.V. (1999). Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clinical Cancer Research, 5(4), 823-829.
16. Hsieh, C.Y., Chen, C.A., Chou, C.H., Lai, K.P., Jeng, Y.M., Kuo, M.L., et al. (2004). Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa/B: Implications for malignant ascites formation and tumor lymphangiogenesis. Journal of Biomedical Science, 11(2), 249-259.
17. Jacobs, I., & Bast, R.C., Jr. (1989). The CA 125 tumour-associated antigen: A review of the literature. Human Reproduction, 4(1), 1-12.
18. Kabawat, S.E., Bast, R.C., Welch, W.R., Knapp, R.C., & Colvin, R.B. (1983). Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid and clear cell types. American Journal of Clinical Pathologists, 79(1), 98-104.
19. Kafali, H., Artunc, H., & Erdem, M. (2007). Evaluation of factors that may be responsible for cyclic change of CA 125 levels during menstrual cycle. Archives of Gynecology and Obstetrics, 275(3), 175-177.
20. Kan, Y. Y. Yeh, S.H., Ng, H.T., & Lou, C.M. ( 1992). Effect of menstruation on serum CA125 levels. Asia Oceania Journal of Obstetrics and Gynaecology, 18(4), 339-343.
21. Kenemans, P., van Kamp, G.J., Oehr, P., & Verstraeten, R.A. (1993). Heterologous double-determinant immunoradiometric assay CA 125 II: Reliable second-generation immunoassay for determining CA125 in serum. Clinical Chemistry, 39(12), 2509-2513.
22. King, R.C., & Stansfield, W.D. (2002). A dictionary of genetics. New York: Oxford University Press.
23. Kui Wong, N., Easton, R.L., Panico, M., Sutton-Smith, M., Morrison, J.C., Lattanzio, F.A., et al. (2003). Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. Journal of Biological Chemistry, 278(3)), 28619-28634.
24. Matias-Guiu, X., & Prat, J. (1998). Molecular pathology of ovarian carcinomas. Virchows Archiv, 433(2), 103-111.
25. Meden, H., & Kuhn, W. (1997). Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: A new prognostic factor. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 7/(2), 173-179.
26. Meden, H., Marx, D., Fattahi, A., Rath, W., Kron, M., Wuttke, W., et al. (1994), Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy. Journal of Cancer Research and Clinical Oncology, 120(6), 378-381.
27. Mukhopadhyay, D., & Datta, K. (2004). Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Seminars in Cancer Biology, 14(2), 123-130.
28. Nussbaum, R.L., McInnes, R.R., Willard, H.F. (Eds.). (2001). Thompson and Thompson genetics in medicine (6th ed.). Philadelphia: Saunders.
29. Nustad, K., Onsrud, M., Jannson, B., & Warren, D. (1998). CA125-epitopes and molecular size. International Journal of Biological Markers, 13(4), 196-199.
30. Ribatti, D. (2005). The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: A historical review. British Journal of Haematology, 128(3), 303-309.
31. Robertson, D.M., Pruysers, E., Burger, H.G., Jobling, T., McNeilage, J., & Healy, D. (2004), Inhibins and ovarian cancer. Molecular and Cellular Endocrinology, 225(1-2), 65-71.
32. Roskelley, C.D., & Bissell, M.J. (2002). The dominance of the microenvironment in breast and ovarian cancer. Seminars in Cancer Biology, 12(2), 97-104.
33. Rubin, S.C., & Sutton, G.P. (2004). Ovarian cancer (2nd ed.). Philadelphia: Lippincott Williams and Wilkins.
34. Seelenmeyer, C., Wegehingel, S., Lechner, J., & Nickel, W. (2003). The cancer antigen CA125 represents a novel counter receptor for galectin-1. Journal of Cell Science, 116(Pt. 7), 1305-1318.
35. Shayesteh, L., Lu, Y., Kuo, W.L., Baldocchi, R., Godfrey, T., Collins, C., et al. (1999). PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genetics, 21(1), 99-102.
36. Sonmezer, M., Gungor, M., Ensari, A., & Ortac, F. (2004). Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: In association with transforming growth factor beta and vascular endothelial growth factor. International Journal of Gynecological Cancer, 14(1), 82-88.
37. Sorak, M., Arsenijevic, S., Lukic, G., Arsenijevic, N., Ristic, P., Pavlovic, S., et al. (2007). Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma. Journal of the Balkan Union of Oncology, 12(1), 99-104.
38. Sun, P.M., Wei, L.H., Luo, M.Y., Liu, G., Wang, J.L., & Mustea, A. (2007). The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 130, 249-257.
39. Sundfeldt, K. (2003). Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule. Molecular and Cellular Endocrinology, 202(1-2), 89-96.
40. Tammela, T., Enholm, B., Alitalo, K., & Paavonen, K. (2005). The biology of vascular endothelial growth factors. Cardiovascular Research, 65(3), 550-563.
41. Tannock, I.F., Hill, R.P., Bristow, R.G., & Harrington, L. (2005). The basic science of oncology (4th ed.). San Francisco: McGraw-Hill.
42. Tong, S., Wallace, E.M., & Burger, H.G. (2003). Inhibins and activins: Clinical advances in reproductive medicine. Clinical Endocrinology, 58(2), 115-127.
43. Verheijen, R.H., von Mensdorff-Pouilly, S., van Kamp, G.J., & Kenemans, P. (1999). CA 125: Fundamental and clinical aspects. Seminars in Cancer Biology, 9(2), 117-124.
44. Villa, R., Folini, M., Perego, P., Supino, R., Setti, E., Daidone, M.G., et al. (2000). Telomerase activity and telomere length in human ovarian cancer and melanoma cell lines: Correlation with sensitivity to DNA damaging agents, International Journal of Oncology, 16(5), 995-1002.
45. Wenham, R.M., Lancaster, J.M., & Berchuck, A. (2002). Molecular aspects of ovarian cancer. Best Practice and Research. Clinical Obstetrics and Gynaecology, 16(4), 483-497.
46. Zhang, L., Yang, N., Katsaros, D., Huang, W., Park, J.W., Fracchioli, S., et al. (2003). The oncogene phosphatidylinositol 3′-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Research, 63(14), 4225-4231.